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ABSTRACT 
Background: Rubella is a self-limiting disease that causes congenital rubella syndrome (CRS) when rubella virus (RV) infects 
women in the first trimester of pregnancy.  
Objective: To assess a population of pregnant women attending antenatal clinics in two tertiary hospitals in southwestern 
Nigeria for anti-RV IgG and IgM in order to determine the proportions susceptible to the viral infection and infectious to their 
fetuses.   
Method: Ninety consenting pregnant women were consecutively recruited and aseptically bled for the study. The sera were 
screened with commercial ELISA kits for anti-rubella virus IgG and IgM. Due to the controls and calibrators included in the 
tests, the IgG test was performed on 89 sera while all 90 samples were screened for IgM. 
Results: Of the 89 pregnant women tested for anti-RV IgG, 86 (96.6%) were positive with protective serum concentrations of the 
antibody. Only six (6.7%, 95% CI: 1.5-11.8%, n = 90) women were positive for anti-RV IgM with 5 (5.6%, 95% CI: 0.8-10.3%) 
having both anti-RV IgG and IgM. Overall, three (3.4%) of the women were susceptible to RV infection, one (1.1%) of these in 
the first trimester of gestation was probably infectious.  
Conclusion:  Majority of the pregnant women had protective levels of anti-RV IgG antibody although susceptibility to rubella 
as well as level of infectiousness were low. Intensification of rubella immunization of all females of child-bearing age in Osun 
and Oyo States is advocated. 
 
Keywords: Prevalence, Rubella, Antibodies, Pregnant women, Southwestern Nigeria. 
 
INTRODUCTION 
Rubella, a vaccine-preventable viral disease, is 
predominantly a human disease that occurs between 
infancy and puberty (1). As a mild exanthematous 
disease, it is associated with low-grade fever, 
lymphadenopathy, headache, malaise, mild coryza, 
and conjunctivitis with a short-lived (acute) 
maculopapular rash (2, 3, 4). The etiologic agent - 
rubella virus (RV) - is an enveloped, positive-sense, 
ssRNA virus in the genus Rubivirus of the family 
Togaviridae. Individuals infected with RV are most 
infectious when the rash is erupting, but they may 
shed virus from 7 days before to 14 days after the 
onset of rash. Following exposure, the incubation 
period before onset of symptoms is usually 14–18 
days (range 12–23 days) (5). 
 
Prior to the introduction of immunization programs, 
rubella was endemic worldwide and peak infection 
occurred in the 5-9 year-old age group. After vaccine 
implementation, the disease shifted from children to 
young adults until its virtual elimination from North 
America and Europe in recent years (6, 7). In tropical 
countries however, epidemics still occur but the lack 
of effective monitoring programs coupled with the 
absence of serious clinical symptoms in affected 
children, make  the epidemics difficult to assess (8). In 
countries that have not implemented vaccination 
programs, infection at an early age is still the norm, 
with high seroconversion rates found in both 
preschool populations and in the 5 to 9 year-old age 
group (9). However, a substantial number of women 
of childbearing age (10-25%) were reportedly 
susceptible to rubella (10). 
 
Cell-mediated and humoral immunity develop in 
humans following natural RV infection and with 
rubella immunization (11). Antibodies produced 
against RV comprise the primary immunoglobulin M 
(IgM) and later IgG which are the markers of current 
RV infection and past infection or protective 
immunity respectively. With natural infection, RV-
specific IgM antibodies become detectable within 3–4 
days and IgG antibodies within one week of the onset 
of rash while following rubella vaccination, the 
appearance of RV-specific IgM and IgG antibodies is 
somewhat delayed and peak levels are lower 
compared to natural infection. Rubella-specific IgM 
can often be detected in individuals up to two months 
after illness and in a decreasing percentage of 
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individuals up to six to seven months after natural 
infection, vaccination and re-infection (11). 
Vaccination of children and mothers with RV vaccine 
is capable of conferring herd immunity that interrupts 
RV transmission. Vaccinated or naturally-infected 
mothers with subsequent seroconversion pass 
protective anti-RV IgG to their newborns (3, 12). It is 
noteworthy however that false-positive IgM test 
results may occur due to cross-reacting IgM 
antibodies to Epstein Barr virus, human parvovirus 
B19, rheumatoid factor or other auto-antibodies.  
 
Though males and females are susceptible, RV 
infection becomes more important when the fetuses of 
pregnant women are infected during the first 
trimester of pregnancy. This usually results in serious 
consequences such as miscarriages, stillbirths and a 
constellation of severe birth defects known as 
congenital rubella syndrome (CRS). Ninety per cent 
(90%) of mothers infected during the first 11 or 12 
weeks of gestation will deliver an infant with CRS 
and the most common congenital defects of CRS are 
cataracts, heart defects and hearing impairment, 
mental/physical retardation et cetera (4, 13). The 
primary objective of the rubella immunization 
program therefore is to prevent CRS.  
 
Immunity to RV is most frequently ascertained by 
detection of specific antibodies using enzyme-linked 
immunosorbent assay (ELISA) or other immunoassay 
methods (5, 14, 15). In Nigeria, Odelola et al. (16) in a 
multicenter study involving Northern, Eastern and 
Western Nigeria, reported that an average of 68% of 
the Nigerian population possessed rubella virus 
antibodies while Pennap et al. (17) reported a 3.9% 
prevalence of RV IgM among pregnant women in 
Makurdi, Benue State. Other studies among pregnant 
women detected rubella IgG antibodies of 68.5% in 
Ibadan (18), 54.1% in Maiduguri (19) and 76% in 
Lagos (20). The present study was conducted to 
determine the proportion of pregnant women with 
anti-rubella virus IgG and IgM in two tertiary 
hospitals in southwestern Nigeria; to assess the rate of 
susceptibility to rubella virus infection and determine 
the possibility of vertical transmission of the virus.   
 
MATERIALS AND METHODS 
Study area and population 
This study was carried out in Wesley Guild Hospital, 
Ilesa, Osun State and Jericho Nursing Home, Ibadan, 
Oyo State between October, 2011 and May, 2012.  
Wesley Guild Hospital is located in Ilesa West local 
government area (LGA) of Osun State while Jericho 
Nursing Home is in Ido LGA, Oyo State.   Figure 1 
shows the demographics of the women. 
 
Study design  
For this study, a cross-sectional, hospital-based design 
was employed following ethical approval by the 
Health Research Ethical Committee of the College of 
Health Sciences, Osun State University, Osogbo.  A 
designated physician (Obstetrician) in the two 
hospitals discussed the objectives and procedures of 
this study with pregnant women visiting the 
antenatal clinic of both hospitals. Ninety pregnant 
women that consented to participate in the study 
were consecutively recruited. Each pregnant woman 
provided pertinent demographic data that were 
obtained through interviewer-administered 
questionnaires. These data included age, report of 
MMR vaccination, educational status, marital status, 
trimester of pregnancy, number of pregnancy (parity), 
and present/past experience of skin rash, history of 
family member with skin rash and knowledge of 
rubella. 
 
Blood sample collection/serum preparation 
About 5 ml blood sample was aseptically collected by 
venipuncture from each pregnant woman. Each blood 
sample was dispensed into appropriately labeled 
anticoagulant-free sample tubes, screw-capped and 
left at room temperature for about 45 minutes to 1 
hour, after which it was spun at 3,000 revolutions per 
minute for 10 minutes to separate serum from blood 
clot. The serum was dispensed into correspondingly 
labeled Eppendorf tube and stored at -20oC until 
tested.  
 
Serological analysis of samples 
The sera of the pregnant women were tested for anti-
RV IgG and IgM using commercial ELISA kits - RUB 
IgG ELISA for the quantitative/qualitative 
determination of IgG antibodies and RUB IgM 
“Capture” for the determination of IgM antibodies to 
rubella virus in human serum and plasma (DIA.PRO, 
Diagnostic Bioprobes Srl, Sesto San Giovanni, Milano, 
Italy). The serologic tests and interpretation of results 
were done in accordance with the manufacturer’s 
instructions while optical signals generated were read 
at 450nm with ELISA plate reader (Optic Ivymen® 
System, Model 2100C). Due to the controls and 
calibrators included in the tests, the IgG test was 
performed on 89 sera while all 90 samples were 
screened for IgM. 
 
Interpretation of ELISA results 
According to the IgG ELISA kit protocol, serum 
samples with anti-RV  IgG concentrations < 10 WHO 
IU/ml were considered negative for anti-RV IgG 
antibody while those with concentrations ≥ 10 WHO 
IU/ml were considered positive. The latter titer is 
considered the lowest concentration of IgG that 
provides an effective immunological protection 
against a second infection of RV. Therefore, for the 
purpose of determining the seropositivity and 
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corresponding concentration of anti-RV IgG in each 
serum sample, the lower limit of the serum control 
(i.e. 18 IU/ml of anti-rubella virus IgG equivalent to 
OD of 0.75) was used to estimate the IgG 
concentration. For instance, serum sample 1 recorded 
OD of 1.304 which is equivalent to 31.296 IU/ml of 
anti-RV IgG. The pregnant woman having this sample 
was hence considered seropositive with protective 
level of anti-RV IgG. This estimation was done for 
each of the 89 serum samples.  
 
For the IgM ELISA, serum samples with Sample to 
Cut-off (S/Co) ratio ˃ 1.2 were considered positive for 
anti-RV IgM antibodies while those with S/Co ratio < 
1.0 were considered negative.  Samples with S/Co 
ratio between 1.0 and 1.2 were considered equivocal 
as recommended by the kit manufacturer. 
 
Data analysis 
The results obtained were analyzed using descriptive 
statistics i.e. mean and percentages with 95% 
confidence interval (CI) but in order to prevent report 
of negative values, CI was not estimated for 
proportions close to 0.0% and 100.0%.  For statistical 
comparison of the mean age and educational status of 
the women from Ilesa and Ibadan, independent t-test 
and Chi-square test were used while to establish 
significant differences between groups, we used 
independent t-test (for two groups) and ANOVA (for 
more than 2 groups) for average values of serum 
concentration of anti-RV IgG.  For IgM seropositivity, 
Chi-square test was used and p-values < 0.05 served 
as indicator of statistical significance. The data 
analysis was done with SPSS version 15.0 for 
Windows (SPSS Inc., Chicago, IL).  
 
RESULTS 
The overall age of the study participants ranged from 
19-44 years (yrs) (mean age: 30.8 [95% CI: 29.9-31.7] 
yrs). The demographic characteristics of the pregnant 
women involved in the study are shown in Figure 1.  
It was observed that the pregnant women from Ilesa 
were statistically comparable in age (P = 0.31) and 
educational status (P = 0.18) with those from Ibadan. 
Five pregnant women (3 from Ilesa and 2 from 
Ibadan) were positive for both anti-RV  IgG and IgM 
antibodies giving an overall  prevalence rate of 5.6%  
(95% CI: 0.8-10.3, n = 90).  
FIGURE 1: DEMOGRAPHIC CHARACTERISTICS OF PREGNANT WOMEN INVOLVED IN THE STUDY 
Three pregnant women (two from Ilesa, one from 
Ibadan) were negative for anti-RV IgG; two of the 
three were negative for both anti-RV IgG and IgM 
antibodies.   
These three were considered susceptible to RV 
infection, giving a rubella susceptibility rate of 3.4% 
(n=89).The third pregnant woman (from Ilesa) (1.1%, 
n = 90) who was positive for IgM was probably in the 
acute phase of infection at the time of sample 
collection. She could therefore be a source of vertical 
transmission of the virus to the fetus and to other 
susceptible contacts. 
Eighty-six (96.6%, n = 89) of the pregnant women 
were positive for anti-RV IgG antibody while six 
(6.7%)  (95% CI: 1.5-11.8, n = 90) were positive for 
anti-RV IgM antibody. The proportions of the 
pregnant women from Ilesa and Ibadan with respect 
to results of serologic tests are shown in Figure 2. Sera 
from three pregnant women (two from Ilesa and one 

































































































































































































































Comparison of anti-RV IgG and IgM prevalence rates 
between pregnant women from Ilesa and Ibadan 
revealed statistically insignificant results due to very 
high IgG positivity and very low IgM positivity. 
When  the optical density (OD) of IgG was expressed 
in WHO IU/ml equivalent and the mean value of  
anti-RV  IgG of the women from Ilesa was compared 
with that of the women from Ibadan,  no significant 
difference was observed (P = 0.06, n = 89).  
 
 
FIGURE 2:  DETECTION OF ANTI-RUBELLA VIRUS IgG AND IgM IN PREGNANT WOMEN IN ILESA AND IBADAN 
Comparison of the mean values of  anti-RV  IgG 
concentration of the pregnant women with respect to 
trimester of pregnancy and parity revealed  that they 
were  statistically comparable at  P = 0.62 (n = 89) and  
P = 0.38 (n = 89) respectively. Anti-RV IgG prevalence 
rate among pregnant women in the first and second 
trimester was 95.9% (n = 73) and corresponding IgM 
prevalence rate was 8.1% (n = 74). Out of the 86 
pregnant women positive for anti-RV IgG antibody, 6 
(7.0%) had received rubella vaccination. Comparison 
of the mean serum anti-RV IgG concentration of these 
6 women (28.0 IU/ml, 95% CI: 17.11-38.87) with that 
of the remaining 80 women (28.3 IU/ml, 95% CI: 
26.49-30.05) showed that they were statistically 
comparable (P = 0.96).  
 
DISCUSSION 
In this study, we aimed at determining the proportion 
of pregnant women attending two tertiary hospitals 
in southwestern Nigeria with anti-RV IgG and IgM, 
the proportion susceptible to RV infection and those 
infectious to their unborn children. Our findings 
revealed that a high proportion (96.6%) of the women 
at both study sites were positive for anti-RV IgG 
(Figure 2). While a high anti-RV IgG prevalence rate 
of 95.7% was detected in Ilesa where, to the best of 
our knowledge, no such study had been done before, 
the detection of 97.7% prevalence of anti-RV IgG in 
Ibadan is consistent with similar high prevalence of 
94.2% obtained by Adesina et al. (21) from pregnant 
women in Ibadan. Anti-RV IgG is valuable for all 
pregnant women and women of child-bearing age as 
it protects them and their fetuses against RV infection 
(22). In this study, the recorded responses of the 90 
women tested showed that only six of them had 
received MMR vaccination which indicates that 
majority of those that were anti-RV IgG-positive had 
natural exposure to the virus and had seroconverted 
with protective levels of anti-RV IgG. This 
observation shows that Ilesa and Ibadan could be 
described as endemic for rubella. Comparison of 
mean serum IgG concentrations of women from both 
study sites revealed no significant difference (P = 
0.06), a further indication of comparable endemicity 
of rubella in both locations.   
 
It is noteworthy that the pregnant women 
seropositive for anti-RV IgG and IgM were in the first 
and second trimesters of pregnancy while all the 16 
women in the third trimester were positive only for 
IgG. Anti-RV IgG and IgM prevalence rates among 
women in their first and second trimesters were 95.9% 
(n=73) and 8.1% (n=74) respectively.  This is contrary 
to the findings of Agbede et al. (23) who reported low 
anti-RV IgG and IgM prevalence rates of 7.0% and 
1.1% respectively among 92 pregnant women in their 
first and second trimesters at University of Ilorin 
Teaching Hospital, Ilorin, Kwara State located in 
north-central Nigeria.  This might indicate a higher 
susceptibility of pregnant women in their first and 
second trimesters of pregnancy to RV infection in 
north-central compared to the southwestern Nigeria.  
Probably, regional differences in endemicity of 
rubella accounted for the observed variations. Of the 
six pregnant women (4 from Ilesa and 2 from Ibadan) 
positive for anti-RV IgM, five had protective anti-RV 
IgG. Since these six, reportedly, did not receive 
rubella vaccination, it can be inferred that the five 
women were naturally exposed to the virus.  
 
The prevalence rate of anti-RV IgM was low among 
the women in both study sites (Figure 2). This 
indicated low rate of rubella virus infection among 
the women as at the time of blood sample collection 
which could be  due to high level of immunity to the 
virus (or RV endemicity) as shown by very high IgG 
prevalence rate. Additionally, only one of these six 














































reported family members having skin rash in the past. 
It could not be confirmed whether the skin rash was 
linked to RV infection or not as five of the women had 
protective levels of serum IgG. Moreover, it was 
observed that these five pregnant women had IgG 
concentrations ˃ 10 IU/ml (i.e. protective levels of 
anti-RV IgG) and were all in the first and second 
trimesters of gestation. This implies that, although 
they might have detectable serum anti-RV IgM 
concurrently with IgG, they were not possibly 
infectious to their fetuses or to their susceptible 
contacts.  
 
Furthermore, two of the pregnant women studied 
were seronegative for both anti-RV IgG and IgM 
while another one was seropositive for only IgM. The 
former were considered susceptible to RV infection as 
they had no report of rubella vaccination and were in 
the first and second trimesters of pregnancy. We 
could, however, not state whether or not they were 
infected with the virus (they probably had 
undetectable levels of anti-RV IgM) as at the time of 
blood sample collection. The third woman, who was 
negative for anti-RV IgG but positive for IgM, was a 
primigravida in the first trimester of gestation and 
had no history of rubella vaccination.  This woman 
was most likely infected with RV as at the time of 
blood collection and was probably infectious to her 
fetus and other susceptible contacts. The fetus of this 
woman thus had a high risk of contracting RV from 
the mother with corresponding high risk of the child 
developing CRS (5). 
 
Also, we observed that six pregnant women (2 from 
Ilesa and 4 from Ibadan) had history  of rubella 
vaccination and were expectedly negative for anti-RV 
IgM with protective levels of anti-RV IgG, the mean of 
which was statistically comparable (P = 0.96) to that 
of the remaining 80 pregnant women having 
protective levels of IgG. While five of these women 
were multiparous, only one was a primigravida.  The 
test used in this study could however not detect 
whether the IgG in the sera of these women was 
induced by rubella vaccine or natural RV infection. 
We also observed that overall, parity did not 
influence IgG concentration (P = 0.38) among the 
pregnant women. 
 
In this study, we observed that the educational status 
of the pregnant women and their knowledge of 
rubella were generally high but the level of receipt of 
MMR vaccination was very low. This could be 
attributed to the non-inclusion of rubella vaccination 
in routine national immunization programme in 
Nigeria, probably due to endemicity of rubella in the 
country. It has been estimated that over 100,000 
infants are born with CRS each year, mostly in 
developing countries that are yet to introduce rubella 
vaccines (24, 25). In this study therefore, there exists a 
likelihood of infecting one unborn child since the only 
infectious mother detected happened to be in the first 
trimester of gestation when up to 90% fetuses of RV-
infected pregnant women may develop CRS (26, 27).  
 
In conclusion, high prevalence of anti-rubella virus 
IgG with protective levels of the antibody was 
reported in pregnant women in this study.   Although 
the rate of susceptibility to rubella as well as 
possibility of vertical transmission of the virus was 
low among the women, there was a chance of an 
expectant mother infecting her fetus with the virus 
with the possibility of RV-induced congenital 
abnormality. It has previously been reported by WHO 
(28) that a low level of susceptibility to RV cannot be 
taken to mean no risk of CRS. Therefore, based on the 
findings of this study, we advocate that RV 
immunization of all females of child-bearing age in 
Osun and Oyo States, and indeed throughout Nigeria, 
be intensified so that the likelihood of infecting their 
fetuses and their contacts during pregnancy can be 
considerably reduced.  
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